Core Viewpoint - Weigao Group (01066) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will spend HKD 1.0605 million to repurchase 195,600 shares [1] - The buyback price ranges from HKD 5.40 to HKD 5.44 per share [1]

Core Viewpoint - Weigao Group (01066) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Categories Company Actions - The company plans to repurchase 195,600 shares at a total cost of HKD 1.0605 million [1] - The buyback price ranges from HKD 5.40 to HKD 5.44 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年11月7日 第一章節註釋： 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫 ...

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 6, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks [1]. Group 1: Buyback Details - China Feihe (06186) repurchased 6.806 million shares for a total of 29.4298 million yuan, representing 0.746% of its total share capital [2]. - Kexin Pharmaceutical-B (02171) repurchased 1.734 million shares for 26.3078 million yuan, accounting for 0.380% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 1.53 million shares for 20.9869 million yuan, which is 0.409% of its total share capital [2]. Group 2: Other Notable Buybacks - Gushengtang (02273) repurchased 493,500 shares for 13.7699 million yuan, representing 3.435% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 2.398 million shares for 10.1066 million yuan, which is 0.100% of its total share capital [2]. - Lianyi Technology-W (09959) repurchased 2.38 million shares for 7.4745 million yuan, accounting for 4.298% of its total share capital [2]. Group 3: Additional Companies - Other companies that conducted buybacks include: - Ruisheng Technology (02018) with 165,000 shares repurchased for 6.5033 million yuan [2]. - MGM China (02282) with 400,000 shares repurchased for 6.3701 million yuan [2]. - Huajian Medical (01931) with 922,000 shares repurchased for 5.9985 million yuan [2]. Group 4: Smaller Buybacks - Companies with smaller buyback amounts include: - Yidian Cloud (02416) with 130,000 shares repurchased for 264,000 yuan [3]. - International Home Retail (01373) with 150,000 shares repurchased for 118,500 yuan [3]. - Mobi Development (00947) with 70,000 shares repurchased for 1.167 million yuan [3].

Core Viewpoint - Weigao Group (01066) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Company Summary - The company plans to repurchase 340,000 shares at a total cost of HKD 1.8368 million [1]

Group 1 - The company, Weigao Group (01066.HK), announced a share buyback on November 6, 2023, spending HKD 1.8368 million to repurchase 340,000 shares at a price range of HKD 5.39 to 5.42 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年11月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 ...

Core Viewpoint - Goldman Sachs reports that Weigao's third-quarter revenue reached 3.26 billion yuan, representing a year-on-year growth of 2.6%, compared to flat growth in the first half of the year [1] Revenue Performance - The pharmaceutical packaging and general medical consumables business continues to face pressure due to insufficient sales growth to offset pricing pressures from volume-based procurement (VBP), particularly in the flushing syringe segment [1] - The growth rate of products used during surgeries is slower than expected in a weak macroeconomic environment [1] - In contrast, revenue from orthopedics, interventional therapy, and blood management businesses showed relatively strong growth [1] Financial Forecast Adjustments - Due to ongoing pricing pressures, Goldman Sachs has lowered its revenue and net profit forecasts for 2025 by 4.4% and 8.5%, respectively [1] - The full-year revenue is now expected to increase by 1.9% year-on-year, while profit is projected to decline by 7.8% [1] Target Price and Rating - The target price has been reduced from 7.8 HKD to 7.4 HKD, while maintaining a "Buy" rating [1]

智通财经APP获悉，高盛发布研报称，威高股份(01066)第三季收入32.6亿元人民币，同比增长2.6%，对 比上半年为同比持平。药品包装及一般医疗耗材业务持续承压，因销量增长不足以抵消带量采购(VBP) 带来的定价压力，尤其冲洗注射器业务，而且手术期间产品在疲弱宏观环境下的推进速度慢于预期。相 反，骨科、介入治疗及血液管理业务收入增长相对较强。考虑到定价压力持续，该行将2025年收入及净 利润预测下调4.4%及8.5%，现预期全年收入同比升1.9%，盈利则同比跌7.8%;目标价由7.8港元降至7.4 港元，维持"买入"评级。 ...

Core Viewpoint - Goldman Sachs reports that Weigao Group (01066) experienced a revenue of 3.26 billion RMB in Q3, reflecting a year-on-year growth of 2.6%, which is flat compared to the first half of the year [1] Revenue Performance - The pharmaceutical packaging and general medical consumables business continues to face pressure due to insufficient sales growth to offset the pricing pressure from volume-based procurement (VBP), particularly in the flushing syringe segment [1] - The growth rate of products during surgeries is slower than expected in a weak macroeconomic environment [1] - Conversely, revenue growth in orthopedics, interventional therapy, and blood management segments is relatively strong [1] Forecast Adjustments - Due to ongoing pricing pressures, the company has revised its revenue and net profit forecasts for 2025 down by 4.4% and 8.5%, respectively [1] - The new expectation for full-year revenue is a year-on-year increase of 1.9%, while profit is anticipated to decline by 7.8% [1] Target Price and Rating - The target price has been reduced from 7.8 HKD to 7.4 HKD, while maintaining a "Buy" rating [1]